Ledger · 2026-09-05 · Chemical Engineering / Materials Science
Chitosan-Modified Bentonite (CMB) Powder via Coprecipitation
Rejected
This concept did not clear the framework. The reasoning is published in full below.
What the assessment found
| Incumbent benchmark | Anionic Polyacrylamide (APAM) |
| Entry application | Textile Dye and Heavy Metal Industrial Wastewater Treatment |
| Measured advantage | none |
| Time to first revenue | 6 months |
| Gross margin at parity | 63.8% |
| Startup CapEx | $180,000 |
| Payback from first sale | 20.0 months |
| Capital productivity | 1.2x |
| Regulatory risk | Low — no material regulatory CapEx reported ($0 estimated) |
Why it failed
- Voided by: Negative control / sub-2x, Absence search missing
- No head-to-head evidence
- Margin fails the operating-cost check
- payback_over
- capital_productivity_under
- Absence asserted, search unreported
Assessment
The concept explicitly concedes failure on commercial and performance viability, requiring 5x-10x higher dosing than APAM (10-20 mg/L vs 0.5-2.0 mg/L). This performance deficit forces a negative gross margin at cost-in-use parity. Furthermore, the report lacks a structured Market Absence Ledger.
Also flagged
- Duplicate references inflating the evidence base
- Price parity asserted, not sourced
A rejection is not a claim that the science is wrong. It means the venture case did not survive: the comparator was not what the buyer actually buys, the comparison was not like-for-like, the advantage fell short of a step change, or the capital and time to first revenue were prohibitive.
Assessed 2026-09-05 against seven gates plus the voiding sub-tests. How the method works · Browse all concepts